Abstract
Preliminary data would suggest that the pineal hormone, melatonin (MLT), may enhance tamoxifen (TMX) anti-tumour efficacy. Both MLT and TMX have been used as single agents in the palliative treatment of metastatic neoplasms, other than the classical hormone-dependent tumours, without, however, any clear efficacy. On this basis, a phase II study with TMX plus MLT has been performed in untreatable metastatic solid tumour patients. The study included 25 metastatic solid tumour patients other than breast cancer and prostate cancer (six unknown primary tumour; four melanoma; four uterine cervix carcinoma; five pancreatic cancer; three hepatocarcinoma; two ovarian cancer; one non-small-cell lung cancer), for whom no other effective standard therapy was available, because of poor clinical conditions, no response to previous chemotherapies and/or chemotherapy-resistant tumours. Both drugs were given orally every day until disease progression (TMX, 20 mg day-1 at noon; MLT, 20 mg day-1 in the evening). Three patients had a partial response (PR) (12%; 95% confidence limits 2-24%) (one cervix carcinoma; one melanoma; one unknown primary tumour). A stable disease (SD) was achieved in 13 other patients, whereas the remaining nine patients progressed. Performance status (PS) improved in 9/25 patients, whose median score increased from 50% to 70%. Finally, a survival longer than 1 year was observed in 7/25 (28%) patients. This phase II study would suggest that the neuroendocrine combination with TMX plus MLT may have some benefit in untreatable metastatic solid tumour patients, either in controlling cancer cell proliferation or improving the PS.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Beutler B., Cerami A. Cachectin: more than a tumor necrosis factor. N Engl J Med. 1987 Feb 12;316(7):379–385. doi: 10.1056/NEJM198702123160705. [DOI] [PubMed] [Google Scholar]
- Broder S., Muul L., Waldmann T. A. Suppressor cells in neoplastic disease. J Natl Cancer Inst. 1978 Jul;61(1):5–11. doi: 10.1093/jnci/61.1.5. [DOI] [PubMed] [Google Scholar]
- Inge T. H., Hoover S. K., Susskind B. M., Barrett S. K., Bear H. D. Inhibition of tumor-specific cytotoxic T-lymphocyte responses by transforming growth factor beta 1. Cancer Res. 1992 Mar 15;52(6):1386–1392. [PubMed] [Google Scholar]
- Knabbe C., Lippman M. E., Wakefield L. M., Flanders K. C., Kasid A., Derynck R., Dickson R. B. Evidence that transforming growth factor-beta is a hormonally regulated negative growth factor in human breast cancer cells. Cell. 1987 Feb 13;48(3):417–428. doi: 10.1016/0092-8674(87)90193-0. [DOI] [PubMed] [Google Scholar]
- Lissoni P., Barni S., Cattaneo G., Tancini G., Esposti G., Esposti D., Fraschini F. Clinical results with the pineal hormone melatonin in advanced cancer resistant to standard antitumor therapies. Oncology. 1991;48(6):448–450. doi: 10.1159/000226978. [DOI] [PubMed] [Google Scholar]
- Lissoni P., Barni S., Crispino S., Tancini G., Fraschini F. Endocrine and immune effects of melatonin therapy in metastatic cancer patients. Eur J Cancer Clin Oncol. 1989 May;25(5):789–795. doi: 10.1016/0277-5379(89)90122-3. [DOI] [PubMed] [Google Scholar]
- Lissoni P., Barni S., Meregalli S., Fossati V., Cazzaniga M., Esposti D., Tancini G. Modulation of cancer endocrine therapy by melatonin: a phase II study of tamoxifen plus melatonin in metastatic breast cancer patients progressing under tamoxifen alone. Br J Cancer. 1995 Apr;71(4):854–856. doi: 10.1038/bjc.1995.164. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Maestroni G. J., Conti A., Pierpaoli W. Pineal melatonin, its fundamental immunoregulatory role in aging and cancer. Ann N Y Acad Sci. 1988;521:140–148. doi: 10.1111/j.1749-6632.1988.tb35272.x. [DOI] [PubMed] [Google Scholar]
- Pollak M., Costantino J., Polychronakos C., Blauer S. A., Guyda H., Redmond C., Fisher B., Margolese R. Effect of tamoxifen on serum insulinlike growth factor I levels in stage I breast cancer patients. J Natl Cancer Inst. 1990 Nov 7;82(21):1693–1697. doi: 10.1093/jnci/82.21.1693. [DOI] [PubMed] [Google Scholar]
- Regelson W., Pierpaoli W. Melatonin: a rediscovered antitumor hormone? Its relation to surface receptors; sex steroid metabolism, immunologic response, and chronobiologic factors in tumor growth and therapy. Cancer Invest. 1987;5(4):379–385. [PubMed] [Google Scholar]